Page 26 - Cassava Sciences News Today

SAVA stock remains volatile as speculators place bets on Simufilam, Cassava Sciences's Alzheimer's drug under Phase 3 study.

Investors are taking refuge in holding cash and liquidating their stock portfolios to weather out the impact of rising interest rates as the inflation rate is showing little signs of slowing down.

So far, 2022 has been rough for small-cap stocks. These stocks, however, often have more upside than large-cap stocks, especially during a bull market

So far, 2022 has been rough for small-cap stocks. These stocks, however, often have more upside than large-cap stocks, especially during a bull market

We have used the August return data of the small-cap stocks to come up with the five best and worst performing small-cap stocks in August 2022.

Cassava Sciences has now released positive 100-patient 12-month data. Multiple insiders purchasing its shares on the open market. Click to read my take on SAVA.

Cassava Sciences, Inc. (NASDAQ:SAVA – Get Rating) shares gapped up before the market opened on Friday following insider buying activity. The stock had previously closed at $27.28, but opened at $29.63. Cassava Sciences shares last traded at $29.46, with a volume of 17,774 shares trading hands. Specifically, insider James William Kupiec acquired 2,500 shares of […]

SAN FRANCISCO (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET).In the Green Micro Focus International plc (MFGP) is up over

The small-cap Russell 2000 gained over 10% in July, compared to a jump of 9.1% for the S&P 500. It is the biggest percentage-point outperformance

We have taken the July return data of the small-cap stocks to come up with the ten best and worst performing small-cap stocks in July 2022.